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In thIs Issue news briefs
Patent protections for some genomic diagnostic tests may be at risk
The US Supreme Court's June 2013 decision to invalidate Myriad Genetics' breast cancer gene patent (August 2013 News Briefs, http://www.nature.com/gim/ journal/v15/n8/full/gim2013116a.html) continues to rock the genomic diagnostic testing industry. In late October, a federal judge invalidated the patent protection held by Sequenom, the California-based genetic testing laboratory that introduced testing for cell-free fetal DNA in maternal blood, thus providing the first noninvasive test for Down syndrome. The case was brought on by Sequenom's efforts to block competitors from providing similar tests, claiming patent infringement. The judge ruled that the patent was invalid because it covered a "natural phenomenon," mirroring the language used in the recent Supreme Court decision, and cited it as precedent. In addition, the judge ruled that the methods used to isolate, amplify, and detect fetal DNA were commonly known when the company applied for the patent and did not pass the novelty test. A Sequenom spokesperson immediately stated that the company would challenge the ruling. But if it stands, genomic diagnostic techniques may become difficult to patent and other patents currently in force may fall to similar challenges. Certainly the innovation bar would be raised, forcing companies to show significant technical creativity and true inventiveness before being granted a patent. Despite its small sample size, a study by Stobbe et al. provides an intriguing glimpse at the extent of discoverable chromosomal abnormalities in a population of autistic adults. Using a whole-genome microarray procedure, the research team performed array comparative genomic hybridization (aCGH) analysis on samples obtained from 24 adult patients seen at the Autism Genetics Clinic, University of Washington, Seattle, from July 2009 to April 2012. aCGH, which can identify small deletions and duplications of a few hundred base pairs, has not previously been used in studies of adults diagnosed with autism spectrum disorders. The technique provided diagnostic information for 5 of 24 patients; 1 additional patient was diagnosed with fragile X syndrome. Variants of unknown significance (VUS) presented in an additional 5 patients. Identification of a specific diagnosis was welcomed by families, the investigators report. Even families who received an inconclusive diagnostic finding expressed gratitude for the opportunity to have an updated genetic evaluation. The hope is that, as variants continue to be explored and catalogued, the prevalence of VUS will diminish. The research team points out that one compelling reason to consider genetic testing of autistic adults is that it may provide information useful in counseling siblings of reproductive age.
-Karyn Hede, News Editor
Personal genomics risk predictions vary widely by company see page 85
In these early days of direct-to-consumer personal genome testing, the reliability of tests varies greatly, as does the viability of companies selling the tests to consumers. In a retrospective analysis, Kalf et al. assessed the predictive ability of three commercial vendors confronted with genomic information for a hypothetical population of 100,000 individuals. The research team calculated disease risk using methodologies provided by the companies and publicly available on their websites or in a published white paper that describes the strategies the companies used for calculating disease risk. The investigators selected six diseases for analysis: age-related macular degeneration, atrial fibrillation, celiac disease, Crohn's disease, prostate cancer, and type 2 diabetes. This group of diseases, which represent a range of genetic effects, illustrates how single-nucleotide polymorphism selection and differing formulas used for calculating risk affect individual predictions. The findings demonstrated that the testing methodology available in 2008 had limited predictive ability for atrial fibrillation, type 2 diabetes, and prostate cancer and a "considerable (20-27%) probability" of contradictory results from different companies for age-related macular degeneration and Crohn's disease. The authors note that their study provides what amounts to historical data that could be used in future performance metrics for the industry. In a sign of the volatility of personal genomics as a profit-making enterprise, two of the three companies studied have been acquired by larger life science enterprises, and neither currently offers personal genome testing.
-Karyn Hede, News Editor
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now there's an app for your genome
As personal genomics takes shape and catches on among tech-savvy consumers, perhaps it was only a matter of time before the first personal-genome app appeared. Although not available to the public yet, researchers at Tel Aviv University in Israel have announced development of a smart phone application that would allow people who have had their genomes sequenced to access the information. After undergoing whole-genome sequencing, users would upload their data to the GeneG website for analysis. The software, available at GeneG (http:// www.geneg.org), is designed to query an individual's uploaded genome for genetic information on demand. "For the first time you can take your genome home and look at it whenever you want," the app's creator, Noam Shomron, stated in a news release on the GeneG website. "We are giving you eyes to peer into your genetics." The implication is that as new tests are developed, users could sift their genetic data to search for information pertaining to health risks or personalized treatment such as drug dosing.
Shomron envisions people carrying their genomes with them to the doctor's office. "If we give this power to the general public, it will put pressure on the medical field to catch up with this information," he stated. However, he cautioned, "it should be used with great caution and with sensible interpretation. Some people might not be ready to see all this information about themselves." -Karyn Hede, News Editor rvlsoft/© iStockphoto/Thinkstock
